Form 4: Disc Medicine CFO Joanne Bryce Reports Stock Option Grant and Stock Disposal

Joanne Bryce, CFO of Disc Medicine, Inc., reports the acquisition of stock options and disposal of common stock on January 10, 2024.

Summary

• On January 10, 2024, Joanne Bryce, the Chief Financial Officer of Disc Medicine, Inc. (IRON), reported a transaction involving the company's stock.
• Bryce acquired 27,250 stock options with an exercise price of $63.90.
• These options vest over time, with 25% vesting on January 10, 2025, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• Bryce also acquired 18,165 shares of common stock at $0.00 and disposed of 23,665 shares of common stock.
• Following these transactions, Bryce directly owns 27,250 derivative securities and 23,665 shares of common stock.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting transactions. The stock option grant is a positive sign, but the disposal of shares could raise some concerns.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Negatives

• The disposal of 23,665 shares of common stock by the CFO could be interpreted negatively by investors, although the reason for the disposal is not disclosed.

Risks

• The vesting schedule of the stock options is contingent upon the CFO's continued service, creating a potential risk if she were to leave the company before the options are fully vested.
• The high exercise price of $63.90 for the stock options means they will only be valuable if the stock price increases significantly above that level.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives with similar vesting schedules.
• The exercise price of $63.90 would need to be compared to the current market price of Disc Medicine's stock to determine the potential value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of alignment between management and shareholder interests.
• Employees may see the stock option grant as a sign of the company's commitment to its executives.

Key Dates